INKT logo

MINK THERAPEUTICS INC

INKTNASDAQ
🏆 #4355 by market capEarnings Nov 12US Equity
$777.49▼ $37.55 (−4.83%)
Simulated price
🔔
Track INKT
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$61M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak
No chart data available for INKT.

Trading Snapshot

Day Range
$772.29 – $790.43
52-Week Range
$8.48 – $16.93
Volume
$6.10B
Avg Volume
$6.92B
Shares Outstanding
5.0M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$8M
Last Q Revenue
$2M
P/E Ratio
-5.1
P/S Ratio
0.0x
EPS (TTM)
$-2.26
Dividend Yield
0.00%
Dilution (1yr)
+13.2%

Why Investors Own INKT

  • ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INKT logo

MINK THERAPEUTICS INC

INKT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$12M▲ +17.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▼ −38.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.3M▲ +13.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$9M YoY
StockOtter · stockotter.space

About MINK THERAPEUTICS INC

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$834.04
▲ +7.3% Upside
High Target$926.74
Low Target$628.53
Based on 27 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

MINK THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift INKT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

MINK THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.